Osteonecrosis Treatment Market Scope And Analysis

Report Code : TIPRE00033413
Category : Life Sciences

No. of Pages : 150

Buy Now

Osteonecrosis Treatment Market Scope, Growth, Size and Share by 2030

Buy Now

Osteonecrosis Treatment Market Report Scope

Report Attribute	Details
Market size in 2022	US$ 637.18 Million
Market Size by 2030	US$ 1,021.92 Million
Global CAGR (2022 - 2030)	6.08%
Historical Data	2020-2022
Forecast period	2022-2030
Segments Covered	By Treatment Type Drugs and Surgeries By End User Hospitals Specialty Clinics Ambulatory Surgical Centers
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	Novartis AG Teva Pharmaceutical Industries Ltd Zimmer Biomet Pfizer Inc Stryker Exactech Inc Merck Co Inc Dr Reddy

Regional Analysis

The osteonecrosis treatment market in North America is expected to grow at a significant rate during the forecast period owing to factors such as the high availability and adoption of advanced treatment options, and the concentration of key manufacturers in the region. The US, in particular, records a high adoption rate of osteonecrosis treatments.

The report profiles important players operating in the global osteonecrosis treatment market. These include Novartis AG; Teva Pharmaceutical Industries Ltd.; Zimmer Biomet; Pfizer Inc.; Stryker; Exactech, Inc.; Merck & Co. Inc.; Dr. Reddy’s Laboratories Ltd.; Viatris Inc; and Horizon Therapeutics plc. These leading players focus on expanding and diversifying their market presence and clientele, thereby tapping business opportunities prevailing in the osteonecrosis treatment market.

A few of the key developments by major market players are as Follows:

In May 2022, Regrow Biosciences received an Orphan Drug Designation (ODD) for OSSGROW from the USFDA as well as the European Medicines Agency (EMA). The drug is intended for patients who are suffering from osteonecrosis.
In April 2021, ECI Pharmaceuticals LLC signed an exclusive distribution agreement with AiPing Pharmaceuticals, Inc. The agreement enabled AiPing to handle the sales, marketing, and distribution of ibuprofen 400 mg, 600 mg, 800 mg tablets, and folic Acid 1 mg tablets in the US.
In February 2021, Additive Orthopaedics received FDA approval for the total talus replacement implant designed as a humanitarian-use device for the talus spacer for the patient-specific treatment of avascular necrosis of the talus in the US.